Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer

Stopped early · Phase 2

Conditions studied: Kidney Cancer

In brief

This study is being done to see if we can improve the response of Interleukin-2 by adding Zoledronic acid. The effectiveness of the combination of drugs in kidney cancer is unknown and will be investigated in this study. In particular, this study will evaluate the effect of this combination on kidney cancer and will also examine the safety and side effects of IL-2 with Zoledronic acid.

Key facts

Study ID

NCT00582790

Run by

University of Wisconsin, Madison

People needed

12

Starts

2003-08-01

Expected to finish

2008-09-01

Last updated by the study team

2019-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed renal cell carcinoma with metastasis.
• Must have measurable disease.
• No prior cytokine, chemotherapy, hormonal, or other immuno-based therapies (including vaccine or cellular based) for their renal cancer is allowed. No prior use of bisphosphonates will be allowed. One prior experimental therapy will be permitted as long as > 4 weeks have passed since last drug administration.
• ECOG performance status 0 or 1
• Adequate cardiac function by history.
• Pulse-oximetry > 92% on room air.

You may not qualify if…

• Radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
• Known brain metastases
• Any history of an autoimmune disease (ie. psoriasis, inflammatory bowel disease, etc) must receive clearance by the investigator before being permitted on study due to the potential worsening of those disorders from IL-
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia.
• History of myocardial infarction or hospitalization for congestive heart failure within 12 months of enrollment.
• History of prior malignancy (except basal cell carcinoma resected with curative intent) unless resected or treated with curative intent and disease free for > 5 years.
• Any history of seizures given increased seizure risk with IL-2.
• Organ allograft (transplant) recipients will be excluded given absolute contraindication with IL-2 therapy.
• Pregnant women are excluded
• Patients on systemic steroids (oral or IV) will not be eligible for the study.

Where it is running

• University of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.